Grit Biotechnology

Focus: Grit Biotechnology is a Shanghai-based biotech company focused on tumor-infiltrating lymphocyte (TIL) therapies for oncology and cell therapy applications. The company operates at pre-revenue stage with an early-stage pipeline across multiple cancer and autoimmune indications.

Oncology Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Grit Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Grit Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

28 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GT307 injection

Solid Tumor, Adult

N/A

Clinical Trials (2)

NCT07534813A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors

N/A

Help build intelligence for Grit Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead position in emerging TIL therapy space with 20 active clinical programs spanning oncology, hematologic malignancies, and autoimmune diseases
Exposure to cutting-edge cell therapy platform with potential to address multiple therapeutic areas beyond cancer
China-based biotech with access to large patient populations and emerging market opportunities in Asia

Watch Out For

Early-stage pipeline with no Phase 3 programs and no marketed products—significant development and commercialization risk ahead
Zero current job openings and limited data on funding, revenue, or employee count raises questions about company stability and growth trajectory
Nascent company with sparse public track record; no published scientific literature indexed, making validation of technology platform difficult

Generated by Claude from Grit Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT06397963Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours

N/A

GT316

Solid Tumor

N/A

Clinical Trials (1)

NCT06145802Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)

N/A

GT201 in combination with PD-1 inhibitors

HNSCC

N/A

Clinical Trials (1)

NCT06190275Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

N/A

GT307 injection

Adult

N/A

Clinical Trials (1)

NCT06453057Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours

N/A

Autologous tumor infiltrating lymphocyte injection（GT201）

Adult

N/A

Clinical Trials (1)

NCT06191900Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

N/A

GT201 injection

Adult

N/A

Clinical Trials (1)

NCT06519669Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer

N/A

GT201 injection in combination with teraplizumab injection

Adult

N/A

Clinical Trials (1)

NCT06235242GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

N/A

GT307 injection

Adult

N/A

Clinical Trials (1)

NCT06819280Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer

N/A

IB-T101 injection

Advanced Clear Renal Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT06819293IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase 1

GT729 Injection

cGVHD

Phase 1

Clinical Trials (1)

NCT07253259A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)

Phase 1

GT719 Injection

Autoimmune Diseases

Phase 1

Clinical Trials (1)

NCT07122076GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

Phase 1

TIL injection

Solid Tumors, Adult

Phase 1

Clinical Trials (1)

NCT06088472TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Phase 1

GT801 Injection

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 1

Clinical Trials (1)

NCT07205315A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Phase 1

GT719 Injection

Hematological Malignancy (Leukemia- Lymphoma)

Phase 1

Clinical Trials (1)

NCT07131254A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

Phase 1

Autologous tumor infiltrating lymphocyte injection（GT201）

Adult Gynecological Tumors

Phase 1

Clinical Trials (1)

NCT06834542Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors

Phase 1

CD19-targeted iNKT Cell Injection

IgA Nephropathy (IgAN)

Phase 1

Clinical Trials (1)

NCT07389499A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

Phase 1

GT719 Injection

Neurological Autoimmune Diseases

Phase 1

Clinical Trials (1)

NCT07021209GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

Phase 1

GT101

Solid Tumors, Adult

Phase 1

Clinical Trials (1)

NCT05430373GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Phase 1

GT801 Injection

Moderate to Severe Refractory Autoimmune Disease

Phase 1

Clinical Trials (1)

NCT07333118A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

Phase 1

GT719 Injection

Auto Immune Disease

Phase 1

Clinical Trials (1)

NCT07132112GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

Phase 1

GT101

Adult

Phase 1

Clinical Trials (1)

NCT06077903GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors